Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PD-L1

- PMLiVE

Alexion’s Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial

Ultomiris-treated patients showed zero relapses with a median treatment duration of 73 weeks

- PMLiVE

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

Both trials showed significant improvement in progression-free survival

- PMLiVE

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

Phase 3 trial results demonstrated a 22% reduction in risk of death versus sorafenib

- PMLiVE

Brainomix set to collaborate with NCIMI to assess AI-powered tech in lung cancer care

The partnership will compare automated evaluation versus observations of medical specialists

- PMLiVE

NHS England launches lung cancer awareness drive in country’s cancer hotspots

Only 57% of those surveyed recognised a persistent cough as a symptom of lung cancer

- PMLiVE

AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma

Tezspire demonstrated reduced annualised rate of asthma exacerbations

- PMLiVE

AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment

Tezspire demonstrated superiority across every primary and key secondary endpoint compared to placebo

- PMLiVE

AstraZeneca’s COVID-19 treatment granted EC approval

Evusheld significantly reduced risk of severe COVID-19 or death in a phase 3 trial

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives CHMP recommendation for prevention of RSV disease in infants

Beyfortus reduced the incidence of medically attended lower respiratory tract infections caused by RSV

- PMLiVE

AstraZeneca’s COVID-19 treatment receives CHMP recommendation for use in EU

Evusheld provided statistically significant protection against progression to severe COVID-19 or death

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy shows promise for advanced biliary tract cancer

Updated results from a phase 3 trial showed the combination treatment reduced the risk of death by 24% versus chemotherapy alone

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvements for lung cancer patients

Data showed a confirmed objective response rate of 53.8% in patients with HER2-mutant metastatic non-small cell lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links